Form 4: Westlake Chemical Director's Future Stock Transactions

A Westlake Chemical Partners LP director reported pre-planned future acquisitions of phantom units and subsequent exercise and partial sale of common units.

Summary

• Lisa A. Friel, a Director of Westlake Chemical Partners GP LLC (the general partner of Westlake Chemical Partners LP), reported transactions in the company's securities.
• On August 6, 2025, Ms. Friel acquired 5,005 Phantom Units, which are the economic equivalent of Common Units, with an exercisable date of August 6, 2026, and an expiration date of September 6, 2026.
• On August 7, 2025, Ms. Friel exercised 4,882 Phantom Units, converting them into 4,882 Common Units.
• Immediately following the exercise, on August 7, 2025, Ms. Friel disposed of 2,441 Common Units at a price of $21.96 per unit.
• After these transactions, Ms. Friel's direct beneficial ownership of Common Units stands at 7,163.
• All reported transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there is a partial sale, the transactions are pre-planned under a 10b5-1 plan, and the director also acquired new phantom units and saw a net increase in common unit holdings, suggesting continued alignment with shareholder interests.

Positives

• Acquisition of 5,005 new Phantom Units indicates a continued future equity stake in the company.
• The net effect of the transactions (exercise of 4,882 units and sale of 2,441 units) resulted in a net increase of 2,441 Common Units in direct beneficial ownership (from an implied 4,722 units to 7,163 units), suggesting continued confidence.

Negatives

• Partial sale of 2,441 Common Units, which could be perceived as a liquidity event rather than a pure investment.

Future Outlook

The filing details pre-planned future transactions by a director, indicating a structured approach to equity compensation and liquidity through a Rule 10b5-1 plan.

Industry Context

This filing is specific to an insider's equity transactions and does not provide broader industry context or trends.

Related Party Transactions

• Transactions involve Lisa A. Friel, a Director of Westlake Chemical Partners GP LLC, the general partner of Westlake Chemical Partners LP, dealing in the issuer's securities.

Stakeholder Impact

• Shareholders may view the director's net increase in common unit holdings as a sign of continued confidence in the company's long-term prospects.
• The partial sale provides liquidity for the insider, which is a common practice for equity compensation.

Key Dates

Recommendation

The filing details pre-planned insider transactions by a director, including the exercise of phantom units and a partial sale of common units, alongside the acquisition of new phantom units. While there's a net increase in common unit holdings, the transactions appear to be part of a routine compensation and liquidity strategy under a Rule 10b5-1 plan, rather than a strong directional signal for the stock. Therefore, it does not warrant a change in investment stance based solely on this filing.

Keywords

Westlake Chemical Partners, WLKP, Form 4, Insider Trading, Director Transactions, Equity, Phantom Units, Common Units, 10b5-1 Plan